{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lipid+Metabolism%2C+Inborn+Errors&page=5", "query": { "condition": "Lipid Metabolism, Inborn Errors", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 501, "total_pages": 51, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lipid+Metabolism%2C+Inborn+Errors&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lipid+Metabolism%2C+Inborn+Errors&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T02:25:49.553Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02083510", "title": "Apolipoprotein CIII Reduction Via Colchicine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hypertriglyceridemia", "Gout", "Pericarditis" ], "interventions": [ { "name": "Colchicine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Scripps Translational Science Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5, "start_date": "2014-02", "completion_date": "2014-05", "has_results": false, "last_update_posted_date": "2014-05-30", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02083510" }, { "nct_id": "NCT05284513", "title": "Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Familial Hypercholesterolemia" ], "interventions": [ { "name": "FH diagnosis program", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Develop and implement tools for quality monitoring", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Develop educational materials", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Conduct educational outreach visits", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Intervene with clinicians and patients to enhance", "type": "BEHAVIORAL" }, { "name": "Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Audit and provide feedback", "type": "BEHAVIORAL" }, { "name": "Implementation strategy package: Stage implementation scale up", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Geisinger Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "26 Years", "maximum_age": null, "sex": "ALL", "summary": "26 Years and older" }, "enrollment_count": 532, "start_date": "2022-09-09", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "Multiple Locations, Pennsylvania", "locations": [ { "city": "Multiple Locations", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05284513" }, { "nct_id": "NCT04026178", "title": "Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Generalized Lipodystrophy" ], "interventions": [ { "name": "Metreleptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aegerion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 11, "start_date": "2018-11-14", "completion_date": "2024-10-31", "has_results": true, "last_update_posted_date": "2025-11-26", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 8, "location_summary": "Birmingham, Alabama • New Orleans, Louisiana • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04026178" }, { "nct_id": "NCT04031469", "title": "A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease", "overall_status": "SUSPENDED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Gut Microbiome", "Gastrointestinal Microbiome", "Autism", "Autism Spectrum Disorder", "Autism Spectrum Disorder High-Functioning", "Alzheimer Disease", "Alzheimer Dementia (AD)", "Alzheimer Dementia", "Alzheimer Disease (AD)", "Crohn", "Crohn Colitis", "Crohn Disease (CD)", "Crohn Disease Colon", "Myalgic Encephalomyelitis", "ME/CFS", "Myalgic Encephalomyelitis (ME)", "Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "Psoriasis", "Psoriasis Annularis", "Psoriasis Chronic", "Chronic Urinary Tract Infection", "Ulcerative Colitis (Disorder)", "Ulcerative Colitis (UC)", "Ulcerative Colitis Acute", "Ulcerative Colitis Chronic", "Multiple Sclerosis", "Multiple Sclerosis (MS) - Relapsing-remitting", "Multiple Sclerosis (MS) Primary Progressive", "Constipation Chronic Idiopathic", "Constipation", "Celiac", "Celiac Disease", "Celiac Sprue", "Lyme Arthritis", "Lyme Borreliosis, Nervous System", "Lyme Disease, Chronic", "Cholesterol", "Cholesterol Level, High", "Cancer", "Colon Cancer", "Amyotrophic Lateral Sclerosis (ALS)", "Amyotrophic Lateral Sclerosis", "Rheumatoid Arthritis (RA)", "Rheumatoid Arthritis - Rheumatism", "Chronic Fatigue Syndrome (CFS)", "PARKINSON DISEASE (Disorder)", "Parkinson Disease", "Parkinson Disease (PD)", "Depression", "Major Depressive Disorder (MDD)", "Depression Disorder", "Depression in Adults", "Anxiety", "Anxiety Disorder Generalized", "Obsessive Compulsive Disorder (OCD)", "Obsessive Compulsive Disorder OCD", "Obsessive - Compulsive Disorder", "Bipolar", "Bipolar 1 Disorder", "Bipolar Disorder (BD)", "Bipolar Disorder I and II", "Bipolar and Related Disorders", "Migraine", "Migraine Disorder", "Diabetes (DM)", "Diabetes", "Lupus", "Lupus Erythematosus", "Epidermolysis Bullosa (EB)", "Mesothelioma", "Mesothelioma Malignant", "IBS (Irritable Bowel Syndrome)", "Irritable Bowel", "IBS - Irritable Bowel Syndrome", "Irritable Bowel Syndrome (IBS)", "Eczema", "Eczema Atopic Dermatitis", "Acne", "Myasthaenia Gravis", "Gout" ], "interventions": [ { "name": "There is no intervention in this study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "ProgenaBiome", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 1000, "start_date": "2019-07-11", "completion_date": "2030-12-10", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "Ventura, California", "locations": [ { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04031469" }, { "nct_id": "NCT06614569", "title": "Long-Term Follow-Up of Subjects Treated With AXO-AAV-GM2 for Tay-Sachs or Sandhoff Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "GM2 Gangliosidosis", "Tay Sachs Disease", "Sandhoff Disease" ], "interventions": [ { "name": "AXO-AAV-GM2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Terence Flotte", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 7, "start_date": "2024-09-17", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "Worcester, Massachusetts", "locations": [ { "city": "Worcester", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06614569" }, { "nct_id": "NCT04273269", "title": "A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "GM1 Gangliosidosis" ], "interventions": [ { "name": "LYS-GM101", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "LYSOGENE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "3 Years", "sex": "ALL", "summary": "Up to 3 Years" }, "enrollment_count": 5, "start_date": "2021-05-11", "completion_date": "2023-05-22", "has_results": false, "last_update_posted_date": "2023-06-09", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04273269" }, { "nct_id": "NCT06451770", "title": "Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hypercholesterolemia", "Hypertriglyceridemia", "Refractory Hyperlipidemia" ], "interventions": [ { "name": "VERVE-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Verve Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2024-10-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 4, "location_summary": "Clearwater, Florida • Miami Lakes, Florida • Port Orange, Florida + 1 more", "locations": [ { "city": "Clearwater", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Port Orange", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06451770" }, { "nct_id": "NCT04020055", "title": "A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "migalastat HCl 150 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amicus Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2022-10-31", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Cleveland, Ohio • Fairfax, Virginia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04020055" }, { "nct_id": "NCT03862274", "title": "Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Batten Disease", "CLN2", "Neuronal Ceroid-Lipofuscinoses" ], "interventions": [ { "name": "CLN2 Treatment", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Jessica Scherr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2018-12-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-10-24", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03862274" }, { "nct_id": "NCT00837824", "title": "Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fabry Disease", "Chronic Kidney Disease, Stage IV (Severe)" ], "interventions": [ { "name": "Fabrazyme (agalsidase beta)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Genzyme, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 20, "start_date": "2002-12", "completion_date": "2003-08", "has_results": true, "last_update_posted_date": "2015-04-07", "last_synced_at": "2026-10-14T02:25:49.553Z", "location_count": 9, "location_summary": "Farmington, Connecticut • Coral Springs, Florida • Kansas City, Kansas + 6 more", "locations": [ { "city": "Farmington", "state": "Connecticut" }, { "city": "Coral Springs", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00837824" } ] }